By Genetic Engineering and Biotechnology News –
Scientists at the University of Glasgow developed a bioengineered bone marrow (BM) model that helped them to evaluate potential use of a combined CRISPR-CAR T cell therapy in the treatment of acute myeloid leukemia.
The team claims the model, which incorporates human cells in a synthetic peptide hydrogel, allows researchers to generate new insights into potential therapies for the disease, and represents an important step forward in being able to carry out medical research without the use of animals. They suggest that the new bioengineered model delivered the kind of human-relevant insights and information that current research methods that rely on animal models have so far been unable to achieve.
